摘要
背景:实验证据显示lncRNA MALAT1与胃癌的增殖能力、侵袭迁移能力、自噬能力和化疗耐药性有关。此外,MALAT1与胃癌的转移和预后有关。本文旨在揭示MALAT1在胃癌中的生物学功能和具体机制。 方法:通过PubMed的全面系统检索,对MALAT1介导胃癌的各种分子机制进行整理和总结。 结果:malat1介导的胃癌参与多种分子机制。例如,MALAT1可以通过抑制miR-122、miR-1297、miR-22-3p、miR-202等的表达来增强胃癌细胞的增殖能力。MALAT1通过参与EMT过程、PI3-Akt等途径促进胃癌的转移和侵袭。MALAT1通过抑制抑癌基因PCDH10的功能增强胃癌的增殖和侵袭能力。MALAT1可通过抑制miR-183,提高自噬标志物水平,提高胃癌细胞的自噬能力。MALAT1通过抑制UPF1和miR-30e水平来增强耐药性。 结论:MALAT1通过多种分子机制与胃癌的发生密切相关。此外,MALAT1还与胃癌患者化疗耐药和预后不良密切相关,提示其有可能作为临床治疗的靶点和预测患者预后的独立危险因素。
关键词: 胃癌,lncRNA,MALAT1,机制,治疗靶点,典型致癌物。
Current Medicinal Chemistry
Title:Molecular Mechanism of the Canonical Oncogenic lncRNA MALAT1 in Gastric Cancer
Volume: 28 Issue: 42
关键词: 胃癌,lncRNA,MALAT1,机制,治疗靶点,典型致癌物。
摘要:
Background: Experimental evidence has shown that lncRNA MALAT1 is related to proliferation ability, invasion and migration ability, autophagy ability, and chemoresistance in gastric cancer. Moreover, MALAT1 is related to metastasis and patient prognosis in gastric cancer. This review aims to reveal the biological functions and specific mechanisms of MALAT1 in gastric cancer.
Methods: After a comprehensive and systematic search in PubMed, various molecular mechanisms of MALAT1 in mediating gastric carcinogenesis are collated and summarized.
Results: MALAT1-mediated gastric cancer is involved in a variety of molecular mechanisms. For example, MALAT1 can enhance the proliferation ability of gastric cancer cells by inhibiting the expressions of miR-122, miR-1297, miR-22-3p, miR-202, etc. MALAT1 enhances the metastasis and invasion of gastric cancer by participating in the EMT process, PI3-Akt and other pathways. MALAT1 enhances the proliferation and invasion of gastric cancer by inhibiting the function of the tumor suppressor gene PCDH10. MALAT1 can increase the autophagy ability of gastric cancer cells by inhibiting miR-183 and increasing the level of autophagy markers. MALAT1 enhances chemical resistance by inhibiting UPF1 and miR-30e levels.
Conclusions: MALAT1 is tightly linked to gastric carcinogenesis through various molecular mechanisms. Moreover, MALAT1 is also closely associated with chemoresistance and poor prognosis in gastric cancer patients, suggesting the possibility of its use as a clinical therapeutic target and a promising independent risk factor for predicting patient prognosis.
Export Options
About this article
Cite this article as:
Molecular Mechanism of the Canonical Oncogenic lncRNA MALAT1 in Gastric Cancer, Current Medicinal Chemistry 2021; 28 (42) . https://dx.doi.org/10.2174/0929867328666210521213352
DOI https://dx.doi.org/10.2174/0929867328666210521213352 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Current Review of Small Molecule Ret Kinase Inhibitors
Mini-Reviews in Medicinal Chemistry Effects and Mechanisms of Anlotinib and Dihydroartemisinin Combination Therapy in Ameliorating Malignant Biological Behavior of Gastric Cancer Cells
Current Pharmaceutical Biotechnology Synthesis and Biological Evaluation of 1, 3-Dihydroxyxanthone Mannich Base Derivatives as Potential Antitumor Agents
Letters in Drug Design & Discovery [6]-gingerol as a Cancer Chemopreventive Agent: A Review of Its Activity on Different Steps of the Metastatic Process
Mini-Reviews in Medicinal Chemistry Inhibitors of HDACs - Effective Drugs Against Cancer?
Current Cancer Drug Targets The Panomics Approach in Neurodegenerative Disorders
Current Medicinal Chemistry Chromatin Remodeling Agents for Cancer Therapy
Reviews on Recent Clinical Trials Focus on the Multimodal Role of Biomarkers in Breast Cancer
Current Pharmaceutical Design Glucose Blood Levels as a Therapeutic Target in Acute Ischaemic Stroke Setting
Current Topics in Medicinal Chemistry New Insight in LPS Antagonist
Mini-Reviews in Medicinal Chemistry Microbial Drug Efflux Proteins of the Major Facilitator Superfamily
Current Drug Targets Glucans as Biological Response Modifiers
Endocrine, Metabolic & Immune Disorders - Drug Targets Interpreting the Mechanisms by which Integrins Promote the Differentiation of Mesenchymal Stem Cells and Integrin Application Prospects
Current Stem Cell Research & Therapy Targeting Histone Deacetylases in Neuroblastoma
Current Pharmaceutical Design New Molecules and Strategies in the Field of Anticancer Agents
Current Medicinal Chemistry - Anti-Cancer Agents Interactions Between Proteins and Platinum-Containing Anti-Cancer Drugs
Mini-Reviews in Medicinal Chemistry Patent Selections:
Current Biomarkers (Discontinued) Screening of Enzyme Inhibitors from Traditional Chinese Medicine
Combinatorial Chemistry & High Throughput Screening RNA Interference-Based Gene Silencing in Mice: The Development of a Novel Therapeutical Strategy
Current Pharmaceutical Design CDK Inhibitors Induce Mitochondria-mediated Apoptosis Through the Activation of Polyamine Catabolic Pathway in LNCaP, DU145 and PC3 Prostate Cancer Cells
Current Pharmaceutical Design